23:00 , Jun 7, 2018 |  BC Extra  |  Preclinical News

Targeting tumor cilia could reverse resistance to kinase inhibitors

A Cell Reports study from Institute of Cancer Research (ICR) researchers and colleagues identified cilia on tumor cells as a new, potentially universal target for sensitizing drug-resistant cells to kinase inhibitors. The research suggests inhibiting...
16:16 , Jul 27, 2017 |  BC Innovations  |  Translation in Brief

Better glioma mouse models

To accelerate the generation of glioma mouse models and find new oncogenic gene fusions, researchers from Memorial Sloan Kettering Cancer Center (MSKCC) have used CRISPR-based gene editing to produce mice in a method designed to...
07:00 , Oct 13, 2016 |  BC Innovations  |  Strategy

Exosomes in the zone

Mark Zipkin, Staff Writer  Having had a slow on-ramp to recognition as more than cellular garbage bags, exosomes are gaining status as a potentially transformational technology, with utility in both diagnostics and therapeutics. But the...
07:00 , Apr 7, 2016 |  BC Innovations  |  Tools & Techniques

Sexy sequencing

Tim Harris, Venture Partner, SV Life Sciences  The days when PhDs were minted based on sequencing a few nucleotides at the end of a piece of nucleic acid are definitely gone. The countless hours spent...
08:00 , Feb 15, 2016 |  BioCentury  |  Emerging Company Profile

Platelet portrait

thromboDx B.V. has found a new repository to mine for disease diagnosis and treatment response: platelets. The company's most advanced programs are for cancer, where the technology could be easier to use and provide a...
07:00 , Oct 5, 2015 |  BC Week In Review  |  Clinical News

EML4-ALK assay: Clinical trial data

An analysis of plasma samples from 24 patients with stage IV NSCLC with known anaplastic lymphoma kinase (ALK) tissue status determined by fluorescence in situ hybridization (FISH) showed that Exosome’s ExoDx Lung ALK assay had...
07:00 , Sep 3, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Anaplastic lymphoma kinase (ALK); EML4-ALK oncogenic fusion protein; MAP kinase kinase 1 (MAP2K1; MEK1); MAP2K2 (MEK2)

Cancer INDICATION: Lung cancer Cell culture and mouse studies suggest combining inhibitors of ALK, MAP2K1 and MAP2K2 could help treat lung cancers positive for the EML4-ALK oncogenic fusion protein . In human lung adenocarcinoma cell...
07:00 , Apr 27, 2015 |  BC Week In Review  |  Clinical News

EML4-ALK assay: Clinical trial data

An analysis of blood samples from 29 patients with NSCLC showed that Exosome’s EML4-ALK assay had 100% specificity for differentiating between the 3 major fusion transcript variants of EML4-ALK. No false positives were detected. Exosome...
08:00 , Nov 13, 2014 |  BC Innovations  |  Distillery Techniques

Technology: Disease models

Approach Summary Licensing status Publication and contact information Disease models Clustered, regularly interspaced short palindromic repeats (CRISPR)-Cas9 genome editing for creating mice bearing oncogenic chromosomal arrangements CRISPR-Cas9 genome editing could be useful for creating mice...
07:00 , Oct 16, 2014 |  BC Innovations  |  Distillery Techniques

Technology: Disease models

Approach Summary Licensing status Publication and contact information Disease models Mouse models of non-small cell lung cancer (NSCLC) based on serial orthotopic transplantation of tumor tissue Mouse studies suggest serial passages of tumor tissues in...